Kornimate/medical-research-clean huggingface dataset:
the effect of lower body positive pressure treadmill training on individuals with chronic stroke

Conditions: Stroke

Summary: stroke is neurological disease characterized by chronic major disability which will cause permanent changes in individuals life. in saudi arabia stroke considered as the main leading of disability and death. it is estimated to be 0.67% in saudi arabia compared to 2.5% of the population in the united states (us). most of individuals have mobility deficit such as walk speed and postural maintenance which lead to increase the risk of fall and decrease activity of daily living (adl). stroke rehabilitation should starts as early as possible to avoid post-stroke complications. several interventions for stroke rehabilitation to improve mobility deficit and posture control continuously being evaluated. one of the ways of stroke rehabilitation is a using of body weight supported treadmill training (bwstt). it is a useful tool to facilitate gait training and recovery after neurological injures. the lower body positive pressure (lbpp) is a treadmill that is enclosed in inflated bag. there is a chamber inside the treadmill that is produce air pressure which is aid in eliminate the uncomfortableness feeling produce by weight bearing during gait. the chamber is supplied with a system provide lbpp aiding in decrease patient weight while walking by giving the patient lifting force from below using air pressure. this helps the patient to walk affectively with minimum weight bearing on the lower extremity. therefore, the purpose of the study is to evaluate the feasibility and effectiveness of lbpp on gait function, balance and quality of life in chronic stroke individuals. the investigators hypothesis that the lbpp will significantly improve gait function, balance, quality of life in chronic stroke patients.


Eligibility criteria:
inclusion criteria: * hemiparesis due to stroke; at least 6 months since the stroke. * independent ambulatory ability with or without assistive device at least 10 meters. * do not have any additional neurological and/or orthopedic deficiencies impairing ambulation. * functional ambulation ≥ 3 on functional ambulation categories * no history of cardiac, respiratory, cardiovascular conditions interferes with protocol, * able to understand simple instructions, * able to control the head and trunk posture. exclusion criteria: * recurrent stroke, * spasticity greater than 3 on modified ashowrth scale, * ataxia, or tremor of lower limb
study of nucel for one and two level lumbar interbody fusion

Conditions: Degenerative Disc Disease; Spondylolisthesis; Spondylosis

Summary: the study is a prospective non-randomized multi-center feasibility clinical trial to establish the safety and efficacy of the nucel® allograft tissue for use in lumbar interbody fusion procedures.

two hundred non-randomized subjects will participate in the study at up to ten clinical sites in the united states. participants will be between 18 and 75 years of age. all subjects will have been established with lumbar spine disease at one or two levels of the lumbar spine that requires lumbar interbody fusion procedure as per the opinion of the treating surgeon. the diseases included in the study are spondylosis, degenerative disc disease and spondylolisthesis. all subjects who meet the inclusion criteria and do not meet the exclusion criteria and who elect to participate and sign the informed consent will be included in the study.

Eligibility criteria:
inclusion criteria: 1. be between 18 and 75 years of age 2. have clinical and/or radiological evidence of stenosis, spondylolisthesis, spondylosis or degenerative disc disease, or at either one or two levels of lumbar spine. 3. in the opinion of the treating surgeon, must already be a qualified candidate for interbody lumbar fusion surgery with supplemental fixation. 4. be likely to return for regular follow-ups until the end of the study period. 5. be willing and able to provide informed consent for study participation. exclusion criteria: 1. previous lumbar spine fusion surgery at operative level. 2. back pain due to acute trauma. 3. clinical, laboratory and/or radiological evidence of back pain secondary to acute or chronic infection, malignancy, other space occupying lesions and metabolic bone demineralization diseases (e.g. osteomalacia, gout, paget's disease etc.) 4. no chronic steroid or chronic prescription nsaid use within three (3) months prior to surgery. 5. any active malignancy, infectious process, or documented chronic autoimmune disease. 6. any other concurrent medical disease or treatment that might impair normal healing process. 7. recent history (within past 6 months) of any chemical or alcohol dependence. 8. morbid obesity (bmi \> 40). 9. currently a prisoner. 10. currently experiencing a major mental illness (psychosis, schizophrenia, major affective disorder) which may indicate that the symptoms are psychological rather than of physical origin. 11. pregnancy at the time of enrollment or planned pregnancy, which would interfere with follow-up imaging.
feasibility study to treat lung cancer with the permanently implantable ldr civasheet®

Conditions: Lung Cancer; Lung Cancer Stage I; Lung Cancer Stage II

Summary: this is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.


Eligibility criteria:
inclusion criteria: * subject signed inform consent * suspected or proven non-small cell lung cancer (nsclc) in the upper lobes of the left or right lung * pre-operative criteria * lung nodule suspicious for nsclc * mass ≤ 7 cm in maximum diameter by ct scan of the chest and upper abdomen * clinical stage i or clinical stage ii * not pregnant or nursing * negative pregnancy test in premenopausal women * fertile patients must use effective contraception * more than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer exclusion criteria: -

Keywords: wedge resection sublobar resection brachytherapy civasheet pd-103 civatech oncology lung cancer lung
hypothermia and circulatory arrest during surgery on the ascending aorta: a comparison between two cooling methods

Conditions: Ascending Aorta Aneurism

Summary: purpose: to compare crash cooling versus gradient cooling methods for patients undergoing planned surgery on the ascending aorta in deep hypothermic circulatory arrest. to investigate the impact of hypothermia and circulatory arrest on the coagulation, stress-response, and cerebral outcome. background: cooling to 18 °c using extracorporeal circulation allows for circulatory arrest during surgery on the ascending aorta. two different methods are used either lowering the temperature of the blood by 10 °c at a time, gradient cooling, or as cold as possible, crash cooling. the distribution of hypothermia is expected to be different for the two methods, the latter predominantly cooling the body core. the influence on the physiological response is expected to vary with the two methods. the surgical procedure and the cooling greatly elicit a stress response and the coagulation is profoundly influenced. there can be adverse effects on the neurological outcome due to the procedure. the two methods are considered equal, but have never been subjected to comparison. the surgery and circulatory changes can have a negative influence on the cerebral outcome . methods: twenty patients between 18 and 80 yrs randomized either to crash cooling or gradient cooling, ten patients in each group.. patients with severe comorbidities or known coagulopathy are excluded. anesthesia and operation as performed routinely in the department. the primary endpoint is duration of cooling, secondary endpoints include coagulation parameters (thromboelastography, clot stability), stress response parameters (adhesion molecule expression on endothelial cells, oxidative stress analysis, inflammatory markers), neuropsychological tests, mri of the cerebrum, markers of cerebral ischemia, and ultrasound imaging of the great vessels for detection of air bubbles. baseline values are obtained for all parameters.


Eligibility criteria:
inclusion criteria: * patients scheduled for surgery on the ascending aorta * need for deep hypothermic circulatory arrest during the procedure exclusion criteria: * known coagulopathy * ejection fraction less than 30 % * severe psychiatric or neurological disease * severe liver disease * severely reduced lung function * glomerular filtration rate less than 15 ml/min/1.73 m2

Keywords: extracorporeal circulation deep hypothermic circulatory arrest aortic aneurism neurological injury inflammation coagulation
enhancing muscle health and metabolism in pre-frail middle-aged and older adults

Conditions: Muscle Loss; Muscle Weakness

Summary: to evaluate the effects of protein-enriched soup plus exercise on muscle mass and muscle strength. besides, the investigators use the valued-based healthcare standard set as well as the center for epidemiological studies-depression, charlson's comorbidity index montreal cognitive assessment , and mini nutritional assessment as outcome measures and to use the trial in validate additional supplement protein-enriched soup plus exercise could improve the vitality and health of mid-aged and old adults.

with aging, functions of every organs become to decline. muscle mass, is one of the decline. according to previous research, adults would lose 40% among from aged 20 to 70. if muscle mass decline combining with the decline of muscle strength is so called sarcopenia.when muscle mass decline, infectious risk gets higher, and resilience after illness gets lower. in addition, activity and life quality are also responsible for falling, cognitive difficulty, disability and mortality among seniors. we hope to find out the etiologies of sarcopenia through this program and develop prevention strategy and model to mollify the the negative effect of rapid aging society.

Eligibility criteria:
inclusion criteria: 1. people who aged 50-75 years 2. patients with following characteristics: 3. feeling loss in activity 4. detecting decline in self's walking speed. 5. feeling tired of doing everything. 6. having fell in last year. 7. people willing to follow the program and cooperate with us for following tracking. 8. people who are neither vegan nor vegetarian 9. people agree and be able to sign the informed consent. 10. the protein of the daily meal are less than 1.0g/kg exclusion criteria: 1. people cannot intake provided meals (e.g.: vegans or vegetarians) or any other who is allergic to our diets. 2. people with any disease affecting their limbs, including: 3. having fracture on limbs in the past 6 months 4. having severe arthritis in the past 6 months 5. any other whom pi recognized as weak control of their nervous system( e.g.: parkinson's disease and stroke). 6. people with intermittent limp caused by peripheral artery diseases 7. people with weak control of mental disorder 8. people with weak control of cardiopulmonary disease 9. people with weak control of malignant tumor 10. people with weak control of kidney diseases (egfr \<60ml/min/1.73) 11. people with visual impairment and hearing disorder which cannot help to complete the program. 12. people who have underwent hormone treatment and planned to undergo hormone treatment during program session. 13. any other condition that pi recognized as not suitable

Keywords: laurel corporation protein-enriched soup
prospective cohort study of synovial biomarkers in the diagnosis and prediction of periprosthetic joint infection

Conditions: Prospective Cohort Study of Synovial Biomarkers in the Diagnosis and Prediction of Periprosthetic Joint Infection

Summary: prosthetic joint infection (pji) is one of the severe complications following arthroplasty. with the global aging population, the number of patients undergoing primary joint replacement surgeries is increasing, leading to a rise in pji cases. although the incidence of pji is generally low, the impact on patients can be catastrophic. once an infection occurs, it is further complicated by the rising global antibiotic resistance, imposing a significant economic burden on patients. therefore, improving the diagnostic rate of pji is crucial. currently, various infection markers are used in the diagnosis of pji. however, there is still a lack of highly sensitive and specific markers to effectively diagnose pji, necessitating the exploration of new infection markers. this study aims to investigate novel infection markers for the diagnosis of pji, providing evidence for its diagnosis and subsequent treatment. in this research, we will prospectively collect data from patients undergoing primary joint replacement and those developing pji from june 2024 to december 2026. these patients will be categorized into non-infection and infection groups. by collecting and analyzing general patient data, surgery-related information, and infection-related indicators from preoperative joint fluid and blood samples, we aim to further evaluate the predictive value of these infection markers for pji.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years old, gender is not limited; 2. the experimental group met the diagnostic criteria of chronic periprosthesis infection after joint replacement according to the 2018 musculoskeletal infection association; the control group was eligible for primary replacement patients who excluded periprosthesis infection. 3. voluntary and signed informed consent. exclusion criteria: 1. patients with immune-related arthritis such as rheumatoid and rheumatism were excluded; 2. radiotherapy and chemotherapy are required due to neoplastic diseases; 3. receiving systemic glucocorticoid therapy (prednisone \> 10mg/ day or equivalent hormone medication); 4. severe immunodeficiency diseases (such as stage 3 hiv, sickle cell anemia, splenectomy, etc.); 5. have a history of drug abuse; 6. use immunosuppressive drugs to treat bone marrow or other transplants; 7. pregnant, parturient and lactating women; 8. participating in other clinical trials; 9. researchers consider other reasons not appropriate for clinical trial participants.

Keywords: prospective cohort study synovial biomarkers diagnosis prediction periprosthetic joint infection
internet-based treatment of stress and anxiety in myocardial infarction with non-obstructive coronary arteries

Conditions: Myocardial Infarction

Summary: patient with myocardial infarction with non-obstructive coronary arteries and takotsubo syndrome often have high levels of stress and anxiety. at present there are no treatment alternatives in this group of patients. previously, cognitive behavioral therapy (cbt), primarily aiming at relieving stress, has been shown to decrease morbidity in patient with myocardial infarction with obstructive coronary arteries. the present open randomized study aims to decrease stress and anxiety in patients with myocardial infarction with non-obstructive coronary arteries and takotsubo syndrome by an internet-based cbt focusing on stress and anxiety.


Eligibility criteria:
inclusion criteria: * a suspected diagnosis of minoca or takotsubo syndrome with coronary angiography without diameter stenosis ≥50% * age 35-80 years * admission-ecg with sinus rhythm * pss-14 ≥ 25 and/or hads-a ≥ 8 during admission * reading and writing proficiency in swedish * computer/internet access and literacy exclusion criteria: * strong clinical suspicion of myocarditis * spontaneous coronary artery dissection * acute pulmonary embolism * acute myocardial infarction type 2 * cardiomyopathy other than takotsubo syndrome * a previous myocardial infarction due to cad * expected poor compliance to behavioural therapy * not likely to survive \> one year due to for example cancer

Keywords: myocardial infarction non-obstructive coronary arteries takotsubo syndrome
bone marrow transplant trial for patients with refractory severe aplastic anemia

Conditions: Severe Aplastic Anemia

Summary: patients with severe, refractory aplastic anemia have a severe, life threatening disease in their bone marrow. refractory disease means that disease has come back or not responded after receiving one or more immunosuppressive treatments. high dose chemotherapy followed by bone marrow transplantation (bmt) has been used to treat blood diseases like aplastic anemia but complications from graft vs host disease (gvhd) and graft failure have limited the survival for those patients. another study done here at johns hopkins has shown that in patients with other diseases (blood cancers) some immunosuppressive drugs given after the bmt has decreased how often patients had complications of gvhd and engraftment failure. this research is being done to find if this approach will help patients with aplastic anemia who have failed other treatments will have better outcomes.


Eligibility criteria:
inclusion criteria: * patients who have refractory or relapsed saa following treatment with one or more immunosuppressive regimens. * age 6 months - 70 years * patients must meet medical criteria for myeloablative bmt * patients or their parents/guardians and donors must be able to sign consent forms. * patients must be geographically accessible and willing to participate in all stages of treatment. exclusion criteria: * poor cardiac function: left ventricular ejection fraction \<45% as determined by muga or echo. * poor pulmonary function: fev1 and fvc \<50% predicted. * poor renal function * positive leukocytotoxic crossmatch * women of childbearing potential who currently are pregnant (β-hcg+) or who are not practicing adequate contraception * uncontrolled viral, bacterial, or fungal infections
a qualitative assessment of the severity and impact of rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy

Conditions: Arthritis; Polymyalgia Rheumatica; Immune Checkpoint Inhibitors

Summary: to understand the severity and nature of participants experiences during iraes following immune checkpoint inhibitor immunotherapy.

1. to understand the severity and nature of participants experiences during rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, including their functional impact 2. to explore domains relevant to participants experiencing rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, and attitudes to domains identified from the literature

Eligibility criteria:
inclusion criteria the criteria are: * patients aged 18 years and above * english (conversational level) speaking, with the ability to give informed consent * patients with a rheumatologist clinician diagnosis of inflammatory arthritis irae or pmr irae following ici therapy exclusion criteria * acutely life-threatening or worsening cancer * hearing impairment functionally limiting participation in verbal interview

Keywords: arthritis polymyalgia rheumatica immune related adverse events
caregiver enhanced assistance and support for the elderly heart failure patient at hospital discharge (cease-hf)

Conditions: Heart Failure

Summary: close to ninety percent of older heart failure (hf) patients have some cognitive deficits at hospital discharge which may impact their ability to make effective decisions about their healthcare. however, informal care partners (cps) may assist in managing hf when provided with appropriate education and support. the goal of this randomized clinical trial (rct) is to evaluate an intervention which will provide 1) additional teaching on management of hf to the patient and cp following hospital discharge, 2) improved communication with the family physician, 3) a hf decision support tool for oral diuretic management, and 4) a digital talking scale. the investigators believe this intervention will improve outcomes and be cost saving. the investigators hypothesize that enhanced education and support for the cps to assist older hf patients following hospital discharge, combined with improved communication with family physicians, contact with a hf nurse, and simple decision support tools, will lead to earlier recognition of clinical deterioration, and improved patient outcomes. innovative and cost-effective approaches to manage hf patients following hospital discharge are urgently needed in canada.


Eligibility criteria:
inclusion criteria: * primary diagnosis of heart failure (with preserved or impaired left ventricular systolic dysfunction) confirmed with the boston criteria \>= 5 points * 60 years of age or older exclusion criteria: * residence in, or planned discharge to a long-term care facility (ltc) * life expectancy less than 3 months * patient transferred to geriatric rehabilitation unit * no caregiver * residence is more than a 30 minute rive from hospital of discharge * patient refused to participate * caregiver refused to participate * patient referred for cv surgery prior to hospital discharge * patient on iv lasix at or bumetamide at hospital discharge * not on po lasix at hospital discharge * patient currently on dialysis * caregiver unavailable during daytime hours * caregiver has disability, serious mental illness or cognitive dysfunction * patient discharged early * patient enrolled in another randomized controlled trial * patient expired * patient and caregiver unable to speak and read english (patient may be enrolled if nurse can converse minimally with patient and caregiver. s-tofhla will not be done for reading comprehension and questionnaires will be administered orally.) * severe aortic stenosis or severe mitral stenosis

Keywords: heart failure heart diseases cardiovascular diseases health information technology disease management patient care management self care informal caregiver care partner peer support transitional care patient education teach-back clinical decision aid
electrical nerve block for amputation pain

Conditions: Post-Amputation Pain; Phantom Limb Pain; Residual Limb Pain; Stump Pain

Summary: the purpose of the clinical trial is to learn whether electrical nerve block via the altius system is a safe and effective treatment for patients with post-amputation pain.

the altius system is an implanted device designed to electrically block nerve signals and alleviate pain. use of this device may be associated with providing an effective, mechanism-based yet non-destructive, treatment for managing intractable limb pain in amputees. in a given patient, the altius system will be deemed effective if treatment results in 50% reduction of pain score for more than 50% of all pain episodes.

Eligibility criteria:
key inclusion criteria: * age ≥ 21 years old * unilateral amputated leg ≥ 12 months * chronic post amputation pain ≥ 6 months * pain episodes typically lasting ≥ 60 minutes * stable drug regimen ≥ 4 weeks * no changes to medications or prosthesis for 3-month primary study period key exclusion criteria: * implanted with an active implantable medical device (i.e. pacemaker) * confounding source of pain that interferes with reporting of limb pain * uncontrolled diabetes * spasticity preventing full range of motion of involved side * extremely short stump; sits on end * untreated psychological condition (i.e. borderline personality) * condition requiring mri studies or diathermy after device implant * life expectancy of less than 24 months * progressive neurological disease (i.e. multiple sclerosis) * subjects with active local or systemic infection or immunocompromised

Keywords: pain chronic amputation phantom pain stump pain